Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19209618 | ENHANCED OSTEOINDUCTIVE COMPOSITIONS, SYSTEMS, AND METHODS OF MANUFACTURE | May 2025 | March 2026 | Allow | 10 | 1 | 1 | Yes | No |
| 18810714 | TOPICAL SKIN BALM FOR ANTI-AGING AND HEALING PURPOSES | August 2024 | November 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18642534 | COMPOSITIONS AND METHODS RELATING TO POOLED FETAL SUPPORT TISSUE | April 2024 | November 2025 | Allow | 19 | 3 | 1 | Yes | No |
| 18172670 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | February 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18166627 | AMNIOTIC CYTOKINE FORMULATIONS | February 2023 | February 2025 | Abandon | 24 | 2 | 0 | No | Yes |
| 18083019 | Compositions and Manufacture of Allograft Tissue | December 2022 | November 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17934549 | ENCAPSULATED LIVER TISSUE | September 2022 | February 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17879746 | METHOD OF LUBRICATING BODILY TISSUE USING AN AMNION DERIVED THERAPEUTIC COMPOSITION | August 2022 | February 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17794718 | TWO-PART CLOTTING COMPOSITION AND METHODS OF MAKING AND USING THEREOF | July 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17755837 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | May 2022 | June 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17675887 | COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS | February 2022 | February 2026 | Abandon | 48 | 1 | 0 | No | No |
| 17586595 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | January 2022 | January 2026 | Abandon | 48 | 0 | 1 | No | No |
| 17571658 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | January 2022 | January 2024 | Allow | 24 | 2 | 1 | No | No |
| 17569789 | Artificial Placenta And Methods Of Preparation | January 2022 | March 2026 | Allow | 50 | 1 | 0 | No | No |
| 17567200 | PARTICLES COMPRISING DECELLULARIZED OMENTUM | January 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17562443 | Precursor Cells Of Induced Pluripotent Stem Cell (IPSC)-Derived Mesenchymal Stem Cells And Method For Preparing The Same | December 2021 | October 2025 | Allow | 45 | 0 | 0 | Yes | No |
| 17562839 | ENRICHED MULTILAYER AMNION DERIVED TISSUE GRAFT | December 2021 | August 2025 | Allow | 43 | 1 | 0 | No | No |
| 17622217 | PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS FOR TREATING TUMORS | December 2021 | August 2025 | Allow | 44 | 0 | 1 | No | No |
| 17558467 | COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR | December 2021 | February 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17554836 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | December 2021 | May 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17547790 | VENTED WOUND DRESSING BARRIER | December 2021 | January 2024 | Allow | 25 | 1 | 1 | No | No |
| 17530036 | STABLE DRY POWDER COMPOSITION COMPRISING BIOLOGICALLY ACTIVE MICROORGANISMS AND/OR BIOACTIVE MATERIALS AND METHODS OF MAKING | November 2021 | January 2026 | Allow | 50 | 1 | 1 | No | No |
| 17517225 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO | November 2021 | July 2025 | Allow | 44 | 2 | 0 | No | No |
| 17502496 | THREE-DIMENSIONAL TISSUE BODY, METHOD FOR PRODUCING SAME, AND FORMATION AGENT FOR THREE-DIMENSIONAL TISSUE BODY | October 2021 | January 2026 | Allow | 51 | 1 | 0 | Yes | No |
| 17490250 | Biodegradable Polymer Compositions | September 2021 | August 2025 | Allow | 47 | 0 | 0 | No | No |
| 17467385 | Methods for Preparing Therapeutically Active Cells Using Microfluidics | September 2021 | February 2026 | Allow | 54 | 3 | 0 | No | No |
| 17411718 | NERVE GRAFTS AND METHODS OF PREPARATION THEREOF | August 2021 | June 2025 | Allow | 46 | 3 | 2 | Yes | No |
| 17410160 | METHODS OF FORMING BONE INTERFACE SCAFFOLDS | August 2021 | February 2022 | Allow | 6 | 1 | 0 | No | No |
| 17363898 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells | June 2021 | June 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17361611 | PERIVASCULAR STROMAL CELLS FROM PRIMATE PLURIPOTENT STEM CELLS | June 2021 | December 2025 | Abandon | 54 | 1 | 0 | No | No |
| 17353006 | MATERIALS AND METHODS FOR ACCELERATING CARDIOVASCULAR TISSUE REGENERATION | June 2021 | May 2022 | Allow | 11 | 1 | 0 | Yes | No |
| 17341296 | COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF | June 2021 | October 2025 | Allow | 53 | 1 | 0 | Yes | No |
| 17335477 | USE OF SECRETOME OF AMNIOTIC FLUID STEM CELL IN THE TREATMENT OF DRY EYE DISEASE | June 2021 | January 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17323114 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17244644 | HUMAN HEPATOCYTES AND USES THEREOF | April 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17290110 | COMPOSITIONS AND METHODS FOR CRYOPRESERVATION AND RECONSTITUTION OF ENGINEERED TISSUES | April 2021 | December 2025 | Abandon | 56 | 1 | 0 | No | No |
| 17214159 | THREE DIMENSIONAL POROUS CARTILAGE TEMPLATE | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17205932 | CRYOPRECIPITATE COMPOSITIONS AND METHODS OF PREPARATION THEREOF | March 2021 | July 2025 | Allow | 52 | 1 | 0 | Yes | No |
| 17192691 | Methods for Preparing Therapeutically Active Cells Using Microfluidics | March 2021 | February 2022 | Allow | 11 | 3 | 0 | Yes | No |
| 17190351 | PLANT-DERIVED NANOFIBRILLAR CELLULOSE HYDROGEL FOR CELL CULTURE AND CHEMICAL TESTING | March 2021 | January 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17269987 | CRYOPRESERVATION OF CELL MONOLAYERS | February 2021 | September 2025 | Allow | 55 | 2 | 0 | Yes | No |
| 17266904 | METHOD FOR PREPARING LIPOSOMES | February 2021 | October 2024 | Allow | 44 | 1 | 1 | No | No |
| 17170199 | BIOTRANSPLANT FOR TREATING GUM RECESSION AND RESTORING GINGIVAL TISSUE VOLUME | February 2021 | August 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17126449 | PERFUSABLE-TYPE DUAL PROXIMAL TUBULE CELL CONSTRUCT AND PRODUCING METHOD THEREOF FOR APPLYING IN VITRO ARTIFICIALRENAL TISSUE MODEL AND RENAL CELL THERAPY | December 2020 | January 2024 | Allow | 37 | 1 | 1 | No | No |
| 17127221 | CELL ENCAPSULATION DEVICE COMPRISING A PANCREATIC PROGENITOR CELL POPULATION | December 2020 | April 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17125837 | Cancellous Bone Product Including Viable Osteogenic Cells | December 2020 | August 2023 | Allow | 32 | 1 | 0 | No | No |
| 17121639 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | December 2020 | October 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 17120626 | Placental Tissue Grafts And Improved Methods Of Preparing And Using The Same | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17104202 | CONDITIONED MEDIUM FROM HUMAN ADULT LIVER STEM CELLS AND ITS USE IN THE TREATMENT OF LIVER DISORDERS | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 16953709 | METHOD OF HARVESTING MESENCHYMAL STEM CELLS FROM CORD-PLACENTA JUNCTION | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17250058 | PRODUCING METHOD OF THE COLLAGEN-LAMININ MATRIX FOR HEALING ULCERS, BURNS AND WOUNDS OF A HUMAN SKIN | November 2020 | April 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17053200 | METHODS FOR EXP ANDING ADIPOSE-DERIVED STEM CELLS | November 2020 | October 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17052854 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17088090 | LUNG AND AIRWAY PROGENITORS GENERATED FROM HUMAN PLURIPOTENT STEM CELLS AND RELATED TREATMENTS | November 2020 | April 2023 | Allow | 29 | 2 | 0 | No | No |
| 17083045 | METHOD OF MAKING LIPIDS WITH IMPROVED COLD FLOW PROPERTIES | October 2020 | December 2023 | Allow | 37 | 2 | 0 | No | No |
| 17077698 | METHOD OF TREATING GRAFT VERSUS HOST DISEASE | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17073169 | METHOD FOR PRODUCING HYPOPHYSIS PRECURSOR TISSUE | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17044744 | METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS | October 2020 | May 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17043270 | CARDIOMYOCYTE PREPARATION AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2020 | April 2024 | Allow | 43 | 1 | 1 | No | No |
| 17022807 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO | September 2020 | May 2024 | Allow | 44 | 4 | 0 | No | No |
| 17010346 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17009797 | Methods for Preparing Therapeutically Active Cells Using Microfluidics | September 2020 | April 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16997048 | TISSUE FORMS DERIVED FROM MEMBRANOUS TISSUE | August 2020 | November 2025 | Abandon | 60 | 1 | 0 | No | No |
| 16994061 | METHODS OF DETERMINING THE SUITABILITY OF CULTURED THYMUS TISSUE FOR IMPLANTATION INTO HUMANS AND ASSOCIATED METHODS OF USE | August 2020 | August 2024 | Allow | 48 | 2 | 1 | No | No |
| 16969600 | METHOD FOR PREPARING AN IRRADIATED PLATELET LYSATE | August 2020 | December 2024 | Allow | 52 | 1 | 1 | Yes | No |
| 16992136 | METHOD FOR INDUCING OLIGODENDROCYTE PRECURSOR CELLS FROM OCT4-INDUCED HUMAN SOMATIC CELLS THROUGH DIRECT REPROGRAMMING | August 2020 | October 2022 | Allow | 26 | 0 | 0 | Yes | No |
| 16992175 | METHOD FOR PREPARING AN IRRADIATED PLATELET LYSATE | August 2020 | October 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16988117 | ENHANCING THE EFFECT OF CAR-ENGINEERED T CELLS BY MEANS OF NUCLEIC ACID VACCINATION | August 2020 | August 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 16968436 | CHONDROCYTE PROLIFERATION PROMOTER, CHONDROCYTE PROLIFERATION PROMOTION METHOD, SCREENING METHOD FOR CHONDROCYTE PROLIFERATION PROMOTERS | August 2020 | April 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16939204 | BIOMATERIALS FOR BIOLOGICAL TISSUE REPAIR | July 2020 | February 2025 | Allow | 55 | 4 | 0 | Yes | No |
| 16940090 | HUMAN PLURIPOTENT STEM CELL-BASED SCREENING FOR SMOOTH MUSCLE CELL DIFFERENTIATION AND DISEASE | July 2020 | May 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16937777 | HUMAN HEPATOCYTES AND USES THEREOF | July 2020 | April 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16934333 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | July 2020 | February 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 16926436 | EDITING OF CCR2 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION | July 2020 | July 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16912586 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | June 2020 | November 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16956575 | EXOSOME ACTIVE FORMULATION FOR PROMOTING ENDOTHELIAL CELL ANGIOGENESIS, AND PREPARATION METHOD AND APPLICATION | June 2020 | February 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16771927 | EXTRACELLULAR VESICLES PURIFIED FROM DRIED BLOOD CARDS | June 2020 | April 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 16887720 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | May 2020 | September 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16853569 | Therapeutics Using Adipose Cells and Cell Secretions | April 2020 | April 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16753530 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY | April 2020 | March 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16649056 | TISSUE CONSTRUCT, METHODS OF PRODUCING AND USING THE SAME | March 2020 | January 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 16639427 | Ultrathin Interfacial Layer on a Hydrogel to Direct its Surface Properties and Cell Adhesion | February 2020 | June 2023 | Allow | 40 | 1 | 1 | No | No |
| 16785756 | Muscle Derived Cells for the Treatment of Gastro-Esophageal Pathologies and Methods of Making and Using the Same | February 2020 | January 2022 | Allow | 23 | 1 | 0 | No | No |
| 16780050 | Precursor Cells Of Induced Pluripotent Stem Cell (IPSC)-Derived Mesenchymal Stem Cells And Method For Preparing The Same | February 2020 | June 2022 | Abandon | 28 | 3 | 1 | No | No |
| 16747736 | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury | January 2020 | July 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16746141 | ARTIFICIAL PLACENTA AND METHODS OF PREPARATION | January 2020 | October 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16631677 | METHODS OF PRODUCING MULTI-LAYERED TUBULAR TISSUE CONSTRUCTS | January 2020 | November 2024 | Allow | 58 | 1 | 1 | Yes | No |
| 16630188 | ARTIFICIAL TENDON OR LIGAMENT TISSUE PRODUCED USING THREE-DIMENSIONAL MECHANOSIGNALING CELL CULTURE SYSTEM | January 2020 | May 2023 | Allow | 40 | 1 | 1 | No | No |
| 16629070 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC FUNCTION | January 2020 | July 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16730877 | PROCESS OF MAKING An AMNION DERIVED THERAPEUTIC COMPOSITION | December 2019 | February 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16729746 | Variable Density Tissue Graft Composition and Methods of Making and Using the Same | December 2019 | April 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16627528 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS | December 2019 | February 2026 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16697946 | METHODS FOR SCREENING PERSONAL CARE PRODUCTS | November 2019 | April 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16617130 | ENGINEERING FUNCTIONAL BONE ORGANS | November 2019 | December 2021 | Allow | 24 | 0 | 0 | No | No |
| 16696947 | COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE | November 2019 | May 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16614602 | METHODS FOR PREPARING A DECELLULARIZED MUSCLE SCAFFOLD | November 2019 | November 2023 | Abandon | 48 | 1 | 0 | No | No |
| 16686545 | Biodegradable Polymer Compositions | November 2019 | December 2021 | Abandon | 25 | 2 | 1 | No | No |
| 16685942 | Cancellous Bone Product Including Viable Osteogenic Cells | November 2019 | June 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16679908 | NANOFRACTION IMMUNE MODULATORS, PREPARATIONS AND COMPOSITIONS INCLUDING THE SAME, AND ASSOCIATED METHODS | November 2019 | August 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16678521 | COMPOSITIONS AND METHODS FOR OBTAINING FUNCTIONAL BASAL-LIKE CELLS | November 2019 | January 2023 | Allow | 38 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FOX, ALLISON M.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FOX, ALLISON M works in Art Unit 1633 and has examined 263 patent applications in our dataset. With an allowance rate of 73.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.
Examiner FOX, ALLISON M's allowance rate of 73.4% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by FOX, ALLISON M receive 2.23 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FOX, ALLISON M is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by FOX, ALLISON M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.8% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 29.1% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 69.2% of appeals filed. This is in the 55% percentile among all examiners. Of these withdrawals, 44.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 102.6% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.